CCM
PRCT icon

CAAS Capital Management’s Procept Biorobotics PRCT Stock Holding History

CAAS Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-49,093
Closed -$1.23M – 875
2021
Q4 		$1.23M Sell
49,093
-907
-2% -$33.5K 0.03% 409
2021
Q3 		$1.91M Buy
+50,000
New +$1.92M 0.04% 365

Other funds holding PRCT

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAAS Capital Management's PRCT Position: Q1 2022 in Review

CAAS Capital Management sold out of Procept Biorobotics (PRCT) in Q1 2022, closing a stake of 49,093 shares — an estimated $1.23M sold.

CAAS Capital Management first reported a position in PRCT in Q3 2021 and held it in 2 quarters. The position peaked at $1.91M in Q3 2021. 58 funds tracked by Wall St. Rank hold PRCT as of Q1 2022.

  • CAAS Capital Management reported no remaining Procept Biorobotics position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 49,093 Procept Biorobotics shares in Q1 2022, an estimated $1.23M.
  • CAAS Capital Management first reported a position in Procept Biorobotics in Q3 2021 and held it in 2 quarters.
  • CAAS Capital Management's Procept Biorobotics position peaked at $1.91M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.